


香港特別行政區政府
衛生署藥劑事務部

香港九龍南昌街 382 號
公共衛生檢測中心 3 樓



THE GOVERNMENT OF THE HONG KONG
SPECIAL ADMINISTRATIVE REGION
PHARMACEUTICAL SERVICE
DEPARTMENT OF HEALTH

PUBLIC HEALTH LABORATORY CENTRE, 3RD FLOOR,
382 NAM CHEONG STREET,
KOWLOON, HONG KONG.

本署檔號 OUR REF: DH PS 7-10/MED/2
電話 TEL: (852) 2319 8500
圖文傳真 FAX NO.: (852) 2834 5117

18 June 2010

Dr Yeung Chiu-fat, Henry
President
Hong Kong Doctors Union

Ms Iris Chang
President
The Practising Pharmacists Association of Hong Kong

Dear Dr. Yeung and Ms. Chang,

“Avastin”

Thank you for your letter dated 25.5.2010 on the above subject.

I wish to inform you that in Hong Kong, clinical trials are regulated under the Pharmacy and Poisons Regulations. The purpose is to ensure adequate protection of the welfare of the trial subjects, the robustness of the trial protocol and the reliability of the results of the trial. As regards the clinical trial of “Avastin” for use in the treatment of AMD by the Hospital Authority, I have been informed by the Hospital Authority (HA) that HA is currently going through the proper procedures to obtain approval before beginning the trial.

I thank you again for bringing the above matters to my attention.

Yours sincerely,

(A W K Chan)
for Director of Health

c.c. Members of the Legislative Council Panel on Health Services
Dr Chow Yat Ngok, York, Secretary for Food and Health,
Food and Health Bureau
Mr Shane Solomon, Chief Executive, Hospital Authority
Mr K P Tsang, Chairman, Retina Hong Kong
Ms Connie Lau, Consumer Council
Mr Christopher Hickey, Country Director, US FDA